Skip to main content

CORRECTION article

Front. Pharmacol., 20 February 2023
Sec. Pharmacoepidemiology
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1155631

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

This article is a correction to:

  1. Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

    1. Read original article
Yu-Yang Liu&#x;Yu-Yang Liu1†Yi-Yang Qu&#x;Yi-Yang Qu1†Shang Wang&#x;Shang Wang1†Ci-Jun LuoCi-Jun Luo1Hong-Ling QiuHong-Ling Qiu1Hui-Ting LiHui-Ting Li1Ping YuanPing Yuan1Lan WangLan Wang1Jin-Ling Li, Jin-Ling Li1,2*Rong Jiang Rong Jiang1*Rui Zhang Rui Zhang2*
  • 1Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
  • 2Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China

A Corrigendum on
Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

by Liu Y-Y, Qu Y-Y, Wang S, Luo C-J, Qiu H-L, Li H-T, Yuan P, Wang L, Li J-L, Jiang R and Zhang R (2023). Front. Pharmacol. 14:1052546. doi: 10.3389/fphar.2023.1052546

In the published article, there was an error.

A correction has been made to the conclusions of the abstract on page one. This sentence previously stated:

“PAH patients benefit from PDE-5is compared to riociguat, including in hemodynamic parameters, 6MWD, WHO-FC and biomarkers.”

The corrected sentence appears below:

“Compared to PDE5i, PAH patients benefit more from riociguat in hemodynamics, 6MWD, WHO-FC and biomarkers.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: pulmonary arterial hypertension, riociguat, systematic review, meta, analysis, phosphodiesterase-5 inhibitor

Citation: Liu Y-Y, Qu Y-Y, Wang S, Luo C-J, Qiu H-L, Li H-T, Yuan P, Wang L, Li J-L, Jiang R and Zhang R (2023) Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis. Front. Pharmacol. 14:1155631. doi: 10.3389/fphar.2023.1155631

Received: 31 January 2023; Accepted: 13 February 2023;
Published: 20 February 2023.

Edited and reviewed by:

Anick Bérard, Montreal University, Canada

Copyright © 2023 Liu, Qu, Wang, Luo, Qiu, Li, Yuan, Wang, Li, Jiang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Rong Jiang, listening39@163.com; Rui Zhang, zhangrui@qdu.edu.cn; Jin-Ling Li, fanglishanghai@163.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.